Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistance

FANTOM医生网络由6个欧盟国家的8名受益人和12个联系伙伴组成，招募了10名研究人员，并将纳入一个既定的国际研究方案：欧洲间变性淋巴瘤相关恶性肿瘤研究倡议(ERIA)以及一个临床网络：欧洲儿童非霍奇金淋巴瘤组织(EICNHL)。Fantom将宠爱和培养招募的研究人员，使他们成为自信、有能力、独立和人脉深厚的欧洲科学家，并欢迎他们加入这些成熟的网络。这将通过一个通过研究开展的培训方案来实现，并辅之以一个平衡的可转让技能方案，该方案由学术界和产业界的合作者提供关键投入。每个研究员的培训将由个人职业发展计划指导，并由一个博士委员会监督，该委员会明确分配了学术和工业主管。该网络的主要目标是通过参加具有国际竞争力的研究方案并将他们纳入上述网络，对招募的研究员进行培训。该研究计划将解决间变性大细胞淋巴瘤(ALCL)带来的临床问题，其典型特征是ALK表达异常。应用创新的模型系统和多组学技术，其中一些是在单细胞水平上进行的，ALCL的生物学包括免疫系统和肿瘤间质的作用将被揭示。这些数据将用于开发(非侵入性)生物标记物和新的治疗方法，最终将设计临床试验，以解决化疗毒性、过度治疗和耐药性问题。研究和培训活动将不仅包括学术实验室，还将包括关键研究机构、生物技术公司、临床试验机构和制药公司，以实现我们的研究目标。

The FANTOM Doctoral Network (DN) composed of 8 beneficiaries and 12 associated partners in 6 EU countries, recruiting 10 researchers and will be embedded into an established international research programme: The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA) as well as a clinical network: The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). FANTOM will cosset and nurture the recruited researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives welcomed into these established networks. This will be achieved through a training programme conducted through research and complemented by a balanced programme of transferable skills designed with key input from both academic and industrial collaborators. The training of each fellow will be guided by an individual career development plan and supervised by a PhD committee with clearly allocated academic and industrial supervisors. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into the aforementioned networks. The research programme will address the clinical problems posed by Anaplastic Large Cell Lymphoma (ALCL) typified by aberrant ALK expression. Applying innovative model systems and multi-omics technologies, some performed to a single cell level, the biology of ALCL including the roles of the immune system and tumour stroma will be uncovered. These data will be applied to the development of (non-invasive) biomarkers and novel therapeutic approaches that will culminate in the design of clinical trials to address the issues of chemotherapy toxicity, over- treatment and drug resistance. The research and training activities will incorporate not only academic labs but also key research institutes, biotechnology companies, clinical trial bodies and Pharma to realise our research goals.